128 related articles for article (PubMed ID: 25387153)
1. Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.
Andrs M; Korabecny J; Jun D; Hodny Z; Bartek J; Kuca K
J Med Chem; 2015 Jan; 58(1):41-71. PubMed ID: 25387153
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.
Li Q; Wu J; Zheng H; Liu K; Guo TL; Liu Y; Eblen ST; Grant S; Zhang S
Bioorg Med Chem Lett; 2010 Aug; 20(15):4526-30. PubMed ID: 20580230
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
4. PI3K: a potential therapeutic target for cancer.
Chen Y; Wang BC; Xiao Y
J Cell Physiol; 2012 Jul; 227(7):2818-21. PubMed ID: 21938729
[TBL] [Abstract][Full Text] [Related]
5. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
[TBL] [Abstract][Full Text] [Related]
6. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Zhu J; Hou T; Mao X
Drug Discov Today; 2015 Aug; 20(8):988-94. PubMed ID: 25857437
[TBL] [Abstract][Full Text] [Related]
8. Emerging common themes in regulation of PIKKs and PI3Ks.
Lempiäinen H; Halazonetis TD
EMBO J; 2009 Oct; 28(20):3067-73. PubMed ID: 19779456
[TBL] [Abstract][Full Text] [Related]
9. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Finlay MR; Griffin RJ
Bioorg Med Chem Lett; 2012 Sep; 22(17):5352-9. PubMed ID: 22835870
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening.
Giordanetto F; Kull B; Dellsén A
Bioorg Med Chem Lett; 2011 Jan; 21(2):829-35. PubMed ID: 21169017
[TBL] [Abstract][Full Text] [Related]
11. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
12. Chemoproteomic Selectivity Profiling of PIKK and PI3K Kinase Inhibitors.
Reinecke M; Ruprecht B; Poser S; Wiechmann S; Wilhelm M; Heinzlmeir S; Kuster B; Médard G
ACS Chem Biol; 2019 Apr; 14(4):655-664. PubMed ID: 30901187
[TBL] [Abstract][Full Text] [Related]
13. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
14. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
15. TGF-β1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus.
Olieslagers S; Pardali E; Tchaikovski V; ten Dijke P; Waltenberger J
Cardiovasc Res; 2011 Aug; 91(3):510-8. PubMed ID: 21478266
[TBL] [Abstract][Full Text] [Related]
16. Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics.
Shaik A; Kirubakaran S
Front Biosci (Landmark Ed); 2020 Mar; 25(8):1510-1537. PubMed ID: 32114443
[TBL] [Abstract][Full Text] [Related]
17. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
18. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer.
Lundholt BK; Linde V; Loechel F; Pedersen HC; Møller S; Praestegaard M; Mikkelsen I; Scudder K; Bjørn SP; Heide M; Arkhammar PO; Terry R; Nielsen SJ
J Biomol Screen; 2005 Feb; 10(1):20-9. PubMed ID: 15695340
[TBL] [Abstract][Full Text] [Related]
19. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
20. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
